摘要
目的分析贝伐珠单抗联合信迪利单抗治疗肝癌患者的效果。方法队列研究。抽取2020年2月至2023年2月许昌市人民医院收治的56例肝癌患者, 采用随机数字表法分为对照组与观察组, 每组28例。对照组予以靶向药安罗替尼治疗, 观察组予以贝伐珠单抗联合信迪利单抗治疗。对比两组治疗效果、肿瘤标志物[甲胎蛋白(AFP)、癌胚抗原(CEA)、糖类抗原199(CA199)、谷氨酰胺转肽酶(GGT)]水平、免疫功能(CD3^(+)、CD4^(+))水平、不良反应。结果观察组治疗总有效率(78.57%, 22/28)高于对照组(53.57%, 15/28), P<0.05。治疗3个周期后, 观察组AFP、CEA、CA199、GGT水平低于对照组(P<0.05), 观察组CD3^(+)、CD4^(+)水平高于对照组(P<0.05)。对照组不良反应发生率(32.14%, 9/28)与观察组(35.71%, 10/28)比较差异未见统计学意义(P>0.05)。结论贝伐珠单抗联合信迪利单抗治疗肝癌患者可提高治疗效果, 降低肿瘤标志物水平, 改善免疫功能, 且安全性较好。
ObjectiveTo analyze the efficacy of bevacizumab combined with sintilimab in the treatment of liver cancer.MethodsA total of 56 liver cancer patients admitted to Xuchang People’s Hospital from February 2020 to February 2023 were selected for the cohort study.And they wre divided into the control group and the observation group by random number table method,with 28 cases in each group.The control group was treated with the targeted drug anlotinib,and the observation group was treated with bevacizumab combined with sintilimab.The therapeutic effect,levels of tumor markers includingα-fetoprotein(AFP),carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199)and Gamma-glutamyl transpeptidase(GGT),immune function evaluated by cluster of differentiation 3^(+)(CD3^(+))and cluster of differentiation 4^(+)(CD4^(+)),and adverse reactions of the two groups were compared.ResultsThe total effective rate of the observation group(78.57%,22/28)was higher than that of the control group(53.57%,15/28),P<0.05.After 3 cycles of treatment,the levels of AFP,CEA,CA199 and GGT in the observation group were lower than those in the control group(P<0.05).After 3 cycles of treatment,the levels of CD3^(+)and CD4^(+)in the observation group were higher than those in the control group(P<0.05).The incidence of adverse reactions in the control group(32.14%,9/28)was not statistically different from that in the observation group(35.71%,10/28),P>0.05.ConclusionsBevacizumab combined with sintilimab in the treatment of liver cancer patients can improve the therapeutic effect,reduce the levels of tumor markers,improve immune function,and improve the safety.
作者
李永冰
Li Yongbing(Department of Gastroenterology,Xuchang People’s Hospital,Xuchang 461000,China)
出处
《中国实用医刊》
2025年第13期96-99,共4页
Chinese Journal of Practical Medicine
